Novartis AG (NVS)

88.12 +0.32  +0.36% NYSE Jul 8, 20:00 Delayed 2m USD

Novartis Cash from Financing (TTM):

-2.931B for March 31, 2020
View 4,000+ financial data types
Browse...
View Full Chart

Cash from Financing (TTM) Chart

Export Data
Save Image
Print Image

Historical Cash from Financing (TTM) Data

View and export this data going back to 2000. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
March 31, 2020 -2.931B
Dec. 31, 2019 -13.63B
Sept. 30, 2019 -11.97B
June 30, 2019 -10.88B
March 31, 2019 -12.38B
Dec. 31, 2018 -4.244B
Sept. 30, 2018 -7.093B
June 30, 2018 -7.409B
March 31, 2018 -8.891B
Dec. 31, 2017 -7.733B
Sept. 30, 2017 -7.64B
June 30, 2017 -6.045B
March 31, 2017 -4.675B
Dec. 31, 2016 -5.314B
Sept. 30, 2016 -5.786B
June 30, 2016 -7.64B
March 31, 2016 -8.448B
Dec. 31, 2015 -9.176B
Sept. 30, 2015 -7.143B
June 30, 2015 -6.027B
March 31, 2015 -6.215B
Dec. 31, 2014 -8.147B
Sept. 30, 2014 -8.923B
June 30, 2014 -9.235B
March 31, 2014 -9.116B
   
Dec. 31, 2013 -8.769B
Sept. 30, 2013 -8.395B
June 30, 2013 -9.12B
March 31, 2013 -8.273B
Dec. 31, 2012 -6.675B
Sept. 30, 2012 -9.751B
June 30, 2012 -11.39B
March 31, 2012 -16.28B
Dec. 31, 2011 -15.02B
Sept. 30, 2011 -14.86B
June 30, 2011 -3.90B
March 31, 2011 3.607B
Dec. 31, 2010 4.116B
Sept. 30, 2010 8.035B
June 30, 2010 1.274B
March 31, 2010 2.379B
Dec. 31, 2009 2.809B
Sept. 30, 2009 -798.00M
June 30, 2009 -556.00M
March 31, 2009 1.568B
Dec. 31, 2008 -2.573B
Sept. 30, 2008 -1.981B
June 30, 2008 -5.539B
March 31, 2008 -10.53B
Dec. 31, 2007 -9.318B

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

Advertisement

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Benchmarks

Benchmarks
AstraZeneca PLC -3.429B
Gilead Sciences Inc -7.879B
Johnson & Johnson -16.81B

Cash from Financing (TTM) Range, Past 5 Years

Minimum -13.63B Dec 2019
Maximum -2.931B Mar 2020
Average -7.843B
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.